Effectiveness of Vitamin C in reducing morbidity in patients with Dengue fever - A double blinded randomized placebo controlled pilot study.
- Conditions
- Dengue fever
- Registration Number
- SLCTR/2017/028
- Lead Sponsor
- Jonathan Orchard BSc(Hons) MBAcC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- Not specified
1. Male and female patients aged 12-70 years.
2. Previously healthy patients coming with dengue fever
3. Within the first 3 days of fever
4. Positive NS1 dengue antigen
5. Platelet count more than 100 000/mm3
1. Patients under age of 12 years and above 70 years
2. Those who have any evidence of plasma leakage, shock or impeding shock, fluid overload, internal bleeding at that time of recruitment
3. Those who have severe vomiting or inability to take oral fluids
4. Drowsy patients - Drowsiness will be assessed clinically based on appearance followed by glasgow coma scale.
5. Those who have liver failure with clinical or biochemical evidence
6. Those who have AST or ALT more than 100 IU/L on admission
7. Patients with other co-morbidities such as diabetes mellitus, hypertension, ischemic heart disease, bronchial asthma, thyroid disorders etc.
8. Patients who are on other medication (statins, metformin, beta blockers)
9. Patients who are severely dehydrated
10. Patients who get admitted later (more than 3 days after onset of fever)
11. Patients who are extremely obese,- BMI more than 27 kg/m2
12. Patients with known fatty liver disease
13. Patients who have used any alternative medicine eg:- indigenous medicine
14. Patients with diagnosed mental illness
15. Patients with ongoing other infections, malignancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method umber of days need to be hospitalised.<br> [Daily during hospital stay]<br>Number of patients going into leaking phase<br> [Daily during hospital stay]<br>Secondary bacterial infection [Daily during hospital stay]<br>
- Secondary Outcome Measures
Name Time Method one [None]<br>